The Regularization Of COVID-19 Detection Brings Increased Detection
The implementation of nucleic acid testing for the COVID-19 is an important guarantee for the overall promotion of resumption of work and production, as well as an important measure to step up the normalization of epidemic prevention and control. Nucleic acid detection methods include fluorescent quantitative and sequencing, which have high accuracy, but keep the high requirements for site and personnel. The central government requested that the scope of testing be expanded. However, the existing testing methods cannot meet the rapidly growing demand for the COVID-19, thus, companies and laboratories have begun to develop other immunological testing programs.
There are three common laboratory testing methods for viruses, namely virus isolation and identification, immunological testing, and molecular biology methods. Isolation and identification are traditional methods, including chicken embryo inoculation and cell culture, which are low cost but time-consuming. Immunological testing includes colloidal gold, enzyme-linked immunoassay technology, and chemiluminescence technology. Although the cost of colloidal gold and enzyme-linked immunoassay technology is low, the requirements for site and personnel are not high and the accuracy of the test is not high, which is not usually utilized. Chemiluminescence technology, with a high accuracy and a high degree of automation, is the latest immunoassay technology developed after radioimmunoassay, fluorescence immunoassay and time-resolved fluorescence immunoassay. Chemiluminescence technology can support the implementation of testing policies.
The catalysis of the epidemic has accelerated the process of equipping domestic medical institutions with relevant medical instrument, in which the normalization of epidemic prevention and control has brought new increments to detection equipment.
The Development of Immune-Diagnosis Sets the Tone for the Development of Chemiluminescence
IVD is an important carrier of modern laboratory medicine, which provides most of the decision-making information for clinical diagnosis. Immuno-diagnosis is the most important subdivision field of in vitro diagnosis, accounting for 39% of the total. The diagnostic market is driven by the three major rapid developments of domestic aging, per capita medical expenditure growth, and hierarchical diagnosis and treatment. Chemiluminescence is the mainstream technology of immune-diagnosis.
Besides, the new medical infrastructure will become one of the core driving forces for the growth of the medical equipment industry in the next few years. Medical construction is an important topic for new infrastructure in the future. According to recent infrastructure projects, various regions have successively issued medical-related bonds. The amount of funds ranges from tens of millions to billions. It can be seen that all regions are strengthening the construction of new medical infrastructure, in which each segment of medical equipment has benefited.
The Domestic Chemiluminescence Capacity Continues to Expand, And the Domestic Replacement Is Just Right
The domestic chemiluminescence industry has developed rapidly in the past ten years. Data shows that the domestic chemiluminescence capacity has increased from 5 billion yuan in 2011 to 34 billion yuan in 2019, with a compound annual growth rate of 23.7%.
The status of the domestic luminescence industry has also been greatly improved, from a domestic rate of less than 5% in 2010 to close to 20% at present. Although the domestic rate is relatively low, the speed of development is worthy of recognition, which can be seen that expansion of market capacity indicates the continuous release of domestic market demand, and the increase of domestic production rate shows that local enterprises have the potential to compete with international manufacturers.
The cost control of domestic medical insurance has become one of the core medical policies in recent years. The domestic path of chemiluminescence was first realized through the combination of cost performance and high-quality service. Currently, the overseas epidemic continues to spread, and medical markets in various countries are overwhelmed. While the domestic market urgently needs a batch of light-emitting devices with high-quality products and services, local companies can seize this opportunity to turn the tide in the domestic market.
Domestic Chemiluminescence Market Structure
Judging from the current domestic competition pattern, due to its high technical barriers and the relatively late intervention of domestic brands, chemiluminescence is generally still a stage of being monopolized by foreign giants. From the current competitive landscape of the industry, Roche accounts for 29 % of the domestic market share, Beckman for 16%, Abbott for 14%, Siemens for 12%, and domestic brands for 18.8%, which can be seen that there is still a lot of room for substitution.
As a closed system, the threshold of chemiluminescence is high, and the scale of revenue is highly correlated with the cumulative installed capacity, and reagents occupy a considerable proportion. Therefore, the first entrant in the market has an advantage, in which the gradual accumulation of customer resources promotes the rapid explosion of reagent business and brand precipitation is of great significance to customer maintenance and market development.
The domestic chemiluminescence market is roughly divided into three echelons. The main representatives of the first echelon are Shenzhen New Industries, Autobio, and Mindray Medical. All of them have obvious first-mover advantages and a high brand reputation, accumulating more high-quality customer resources, and have a relatively advanced instrument and reagent R&D technology platform as they have invested in higher R&D costs. Besides, there are broad channels for the enterprises in the first echelons, with rapid expansion at home and abroad, large development space, and a certain layout in the top three hospitals. The second echelon is mainly Beijing Leadman, Shanghai Kehua, and Dirui. The third echelon is mainly small medical companies.
We provide more professional and intelligent market reports to complement your business decisions.